Trials / Completed
CompletedNCT00147745
Effects of Colesevelam on How the Body Responds to Insulin in Patients With Type 2 Diabetes
Effects of Colesevelam on Insulin Sensitivity in Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess the potential mechanism of action by which WelChol® (colesevelam) may improve blood glucose control in patients with type 2 diabetes
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Colesevelam | Colesevelam 3.8g for 12 weeks |
| DRUG | Colesevelam matching placebo | Colesevelam matching placebo for 12 weeks |
| DRUG | Insulin glargine (Lantus) | Insulin glargine for 12 weeks |
Timeline
- Start date
- 2005-06-01
- Primary completion
- 2008-01-01
- Completion
- 2008-01-01
- First posted
- 2005-09-07
- Last updated
- 2014-04-02
- Results posted
- 2009-12-04
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00147745. Inclusion in this directory is not an endorsement.